We further studied CEBPA mutations in 871 AML from the TUH cohort and found the mutation in 35.7% of GMP-L (46/129, RR:6.2, p < 0.0001, Supplemental Fig. 4A), the majority of which were bi-allelic mutations (72%, 33/46). The gene discussed is CEBPA; the disease is acute myeloid leukemia.